News
PRPO
6.74
+1.22%
0.08
Weekly Report: what happened at PRPO last week (0408-0412)?
Weekly Report · 17h ago
Weekly Report: what happened at PRPO last week (0401-0405)?
Weekly Report · 04/08 12:15
PRPO Stock Earnings: Precipio Beats EPS, Misses Revenue for Q4 2023
Precipio reported earnings per share of 88 cents for the fourth quarter of 2023. The company reported revenue of $4.33 million. This was 11.65% worse than the analyst estimate for revenue. Precipio also reported results for the third quarter of 2018.
Investorplace · 04/01 14:53
Weekly Report: what happened at PRPO last week (0325-0329)?
Weekly Report · 04/01 12:12
Precipio Inc Schedules Year-End Shareholder Update Call
TipRanks · 03/26 20:53
Precipio Announces Year end 2023 Shareholder Update Call
Specialty cancer diagnostics company Precipio, Inc. Will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company's current core businesses.
Barchart · 03/25 16:00
Weekly Report: what happened at PRPO last week (0318-0322)?
Weekly Report · 03/25 12:15
Weekly Report: what happened at PRPO last week (0311-0315)?
Weekly Report · 03/18 12:13
Weekly Report: what happened at PRPO last week (0304-0308)?
Weekly Report · 03/11 12:08
Weekly Report: what happened at PRPO last week (0226-0301)?
Weekly Report · 03/04 12:12
Weekly Report: what happened at PRPO last week (0219-0223)?
Weekly Report · 02/26 12:32
Weekly Report: what happened at PRPO last week (0212-0216)?
Weekly Report · 02/19 12:34
Weekly Report: what happened at PRPO last week (0205-0209)?
Weekly Report · 02/12 12:19
Precipio And Cardinal Health Sign Distribution Agreement For Its HemeScreen Portfolio Of Molecular Assays For Cancer
Precipio has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Cardinal Health will market and distribute Precipio's portfolio of molecular assays to its customer base of hospitals and other healthcare systems. The company is a specialty cancer diagnostics company.
Benzinga · 02/06 15:00
Weekly Report: what happened at PRPO last week (0129-0202)?
Weekly Report · 02/05 12:32
Weekly Report: what happened at PRPO last week (0122-0126)?
Weekly Report · 01/29 12:14
Precipio's Q4-2023 Cash Burn From Operations Drops Below $100K For The Full Quarter; Precipio's End Of Quarter Cash Balance Changed From ~$1.5M At The End Of Q3-2024, To ~$1.4M As Of Dec 31, 2023
Specialty cancer diagnostics company Precipio, Inc. Is close to breakeven. Cash Burn From Operations declined by over 90% from the previous quarter. The company's end of quarter cash balance increased to $1.4M. Management believes incremental growth is possible to close the gap.
Benzinga · 01/23 15:06
Press Release: Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter Results clearly demonstrate the business's ability to reach breakeven in the near future. Cash Burn from Operations declined by over 90% from the previous quarter.
Dow Jones · 01/23 15:00
Weekly Report: what happened at PRPO last week (0115-0119)?
Weekly Report · 01/22 12:20
Health Care Sector Update for 01/17/2024: ALLK, KKR, PRPO, NTRA
NASDAQ · 01/17 20:56
More
Webull provides a variety of real-time PRPO stock news. You can receive the latest news about Precipio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.